Literature review reveals predominant use of monetary metrics in marine genetic resource valuation, highlighting a narrow focus on drug discovery.
Marine biotechnology is a rapidly growing sector of the ocean economy, but efforts to assess its value, and that of the genetic resources that enable it, remain contentious. Through a comprehensive literature review, we identified 67 distinct valuations of marine genetic resources. We analysed these using the IPBES Values Assessment typology and found a predominance of behaviour-based valuations using economic value indicators to assess monetary benefits from marine drug discovery.
No takes yet. Share an insight, caveat, or question.
Krusberg et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: